S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Seres Therapeutics (MCRB) Stock Price, News & Analysis

$0.78
+0.03 (+4.00%)
(As of 03/27/2024 ET)
Today's Range
$0.75
$0.80
50-Day Range
$0.75
$1.25
52-Week Range
$0.73
$6.87
Volume
3.30 million shs
Average Volume
4.71 million shs
Market Capitalization
$117.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Seres Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
754.5% Upside
$6.67 Price Target
Short Interest
Bearish
12.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$20,371 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($0.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

148th out of 939 stocks

Pharmaceutical Preparations Industry

59th out of 422 stocks

MCRB stock logo

About Seres Therapeutics Stock (NASDAQ:MCRB)

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Stock Price History

MCRB Stock News Headlines

MCRB Apr 2024 1.000 put
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Seres Therapeutics (MCRB) Gets a Buy from TD Cowen
Q4 2023 Seres Therapeutics Inc Earnings Call
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Seres Therapeutics's Earnings: A Preview
Seres Therapeutics Inc MCRB
Seres Therapeutics Inc (MCRB)
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
233
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+754.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-113,720,000.00
Pretax Margin
-90.03%

Debt

Sales & Book Value

Annual Sales
$126.32 million
Book Value
($0.35) per share

Miscellaneous

Free Float
143,308,000
Market Cap
$117.82 million
Optionable
Optionable
Beta
2.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 48)
    President, CEO & Director
    Comp: $1.02M
  • Dr. Lisa von Moltke M.D. (Age 65)
    Executive VP & Chief Medical Officer
    Comp: $725.15k
  • Dr. Teresa L. Young Ph.D. (Age 57)
    R.Ph., Executive VP and Chief Commercial & Strategy Officer
    Comp: $606.33k
  • Mr. David A. Arkowitz M.B.A. (Age 63)
    Executive VP, CFO & Head of Business Development
    Comp: $670.02k
  • Dr. David S. Ege Ph.D. (Age 49)
    Executive VP & Chief Technology Officer
    Comp: $142.71k
  • Dr. Matthew R. Henn Ph.D. (Age 49)
    Executive VP & Chief Scientific Officer
    Comp: $643.83k
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 69)
    J.D., Chief Legal Officer, Executive VP & Secretary
    Comp: $719.55k
  • Ms. Caroline Holda
    Assistant General Counsel

MCRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price target for 2024?

3 brokerages have issued 1-year price targets for Seres Therapeutics' stock. Their MCRB share price targets range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 754.5% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2024?

Seres Therapeutics' stock was trading at $1.40 on January 1st, 2024. Since then, MCRB stock has decreased by 44.3% and is now trading at $0.7802.
View the best growth stocks for 2024 here
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MCRB earnings forecast
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported $0.36 EPS for the quarter, missing analysts' consensus estimates of $0.55 by $0.19. The biotechnology company had revenue of $126.50 million for the quarter, compared to the consensus estimate of $125.67 million. The business's revenue was up 10441.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.70) EPS.

What ETF holds Seres Therapeutics' stock?

Simplify Propel Opportunities ETF holds 550,626 shares of MCRB stock, representing 2.57% of its portfolio.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

Seres Therapeutics (MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.65%), Vanguard Group Inc. (3.98%), Point72 Asset Management L.P. (1.66%), Handelsbanken Fonder AB (0.85%), Northern Trust Corp (0.60%) and Charles Schwab Investment Management Inc. (0.52%). Insiders that own company stock include David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Paula Cloghessy, Teresa L Young and Thomas Desrosier.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MCRB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners